|
Product
|
p16-TAT, Human
|
|
Cat#
|
101-32-26B
|
|
Sequence
|
EPAAGSSMEP SADWLATAAA RGRVEEVRAL LEAGALPNAP
NSYGRRPIQV MMMGSARVAE LLLLHGAEPN CADPATLTRP VHDAAREGFL
DTLVVLHRAG ARLDVRDAWG RLPVDLAEEL GHRDVARYLR AAAGGTRGSN
HARIDAAEGP SDIPDGYGRK KRRQRRR
|
|
Unit/Weight
|
25 μg
|
|
Unit Price
|
$152.00
|
|
Description
|
Cyclin-dependent kinase inhibitors (CDKIs) are proteins that bind to and inhibit the activity of CDKs. Two major classes of CDK inhibitors have been identified. The p16 family (p15, p16, p18 and p19) binds to and inhibits the activities of CDK4 and CDK6. The p21 family (p21, p27, p28 and p57) can bind to broad range of CDK-cyclin complexes and inhibit their activities. CDKIs are capable of suppressing growth, and several lines of evidence strongly suggest that at least some CDKIs may be tumor suppressor proteins.
|
|
Molecular Weight
|
Approximately18.0 kDa, a single non-glycosylated polypeptide chain containing 167 amino acids.
|
|
Purity
|
> 95 % by SDS-PAGE and HPLC analyses.
|
|
Storage
|
This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.
|
|